Sign up to create alerts for Instruments,
Economic Events and content by followed authors
Free Sign Up Already have an account? Sign In
Quotes
All Instrument Types
- All Instrument Types
- Indices
- Equities
- ETFs
- Funds
- Commodities
- Currencies
- Crypto
- Bonds
- Certificates
Please try another search
💰 Hidden Value: These stocks are trading at deep discounts to true worth
Get the list
Abeona Therapeutics CEO sells shares worth $119,500
Published Apr 01, 2025 01:20
In a recent transaction, Seshadri Vishwas, the Chief Executive Officer of Abeona Therapeutics Inc. (NASDAQ:ABEO), sold 25,000 shares of the company's common stock. The shares were sold at a weighted average price of $4.78, amounting to a total value of $119,500. This sale was conducted under a Rule 10b5-1 trading plan that Vishwas adopted on September 18, 2024. According to InvestingPro data, ABEO's stock has shown significant volatility, with the price currently at $4.76, down about 34% over the past year. Analysts maintain a strong buy consensus with price targets ranging from $9.50 to $25.
Following this transaction, Vishwas retains ownership of 1,355,322 shares in the company. The shares were sold in multiple transactions, with prices ranging between $4.71 and $4.81. With a market capitalization of $231 million and an overall Financial Health score of FAIR on InvestingPro, which offers 8 additional key insights about ABEO's performance and outlook in its comprehensive Pro Research Report. Vishwas has committed to providing the company, its shareholders, or the Securities and Exchange Commission with detailed information regarding the specific prices of each transaction upon request.
In other recent news, Abeona Therapeutics Inc. reported a surprising fourth-quarter earnings result for 2024, with an earnings per share (EPS) of $0.50, significantly outperforming the anticipated loss of $0.35 per share. Despite this positive earnings surprise, the company's revenue fell short of projections, recording zero revenue against an expected $100,000. The company maintains a strong cash position, with $98.1 million available, and has increased its manufacturing capacity in anticipation of potential demand for its RDEB treatment. Looking ahead, Abeona anticipates an FDA decision on its lead product, Pradimigene zamytereso, by April 2025. Analysts have noted the potential for significant revenue, estimating over $2 billion in cumulative revenue in the U.S. alone. The company is preparing for the commercial launch of its product, with plans to activate treatment centers by the third quarter of 2025. Abeona's executives have expressed optimism about the company's future, highlighting the potential for two FDA approvals in 2025.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Related Articles
Add Chart to Comment
Confirm Block
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
Report this comment
I feel that this comment is:
Comment flagged
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.